Rate Video

ESMO Breast 2020 | Effects of BMI on PFS in the MONARCH 1 and MONARCH 2 trial

Evandro de Azambuja • 22 May 2020

ESMO Breast 2020

Breast Cancer Abemaciclib

MONARCH 1 MONARCH 2

Evandro de Azambuja, MD, PhD, of the Institut Jules Bordet, Brussels, Belgium, reports small decreases in PFS for obese patients treated with CDK4/6 inhibitors and endocrine therapy in the MONARCH 1 (NCT02102490) and MONARCH 2 (NCT02107703) trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Tumor infiltrating lymphocytes (TILs) as a predictive biomarker in breast cancer

Evandro de Azambuja • 12 Sep 2022

Adjuvant endocrine therapy for breast cancer: optimal durations and regimens

Evandro de Azambuja • 12 Sep 2022

MONARCH: Chemo-free options for triple-positive metastatic breast cancer

Evandro de Azambuja

Nationwide study by the BCR and BSMO on the effect of surgery on mBC patients

Evandro de Azambuja • 22 May 2020

Related Videos

IMpassion130 study: improvement in OS and PFS for IIT and PD-L1+ populations with mTNBC

Highlights in breast and gynecological cancer at ESTRO 2022

Drug shortages around the world: why communication is key

HER-2 conversion: a phenomenon in trastuzumab resistance